FibroGen (NASDAQ:FGEN) Trading Up 5.7%

FibroGen Inc (NASDAQ:FGEN) shares were up 5.7% on Friday . The stock traded as high as $37.59 and last traded at $36.99, approximately 1,002,000 shares were traded during trading. An increase of 36% from the average daily volume of 736,316 shares. The stock had previously closed at $34.98.

Several equities research analysts have recently weighed in on FGEN shares. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. Mizuho reiterated a “positive” rating and set a $72.00 target price (up previously from $65.00) on shares of FibroGen in a research note on Monday. ValuEngine raised shares of FibroGen from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Zacks Investment Research cut shares of FibroGen from a “strong-buy” rating to a “hold” rating in a report on Thursday. Finally, TheStreet raised shares of FibroGen from a “d+” rating to a “c” rating in a report on Tuesday, August 13th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $58.33.

The stock has a market capitalization of $3.09 billion, a PE ratio of -35.91 and a beta of 1.84. The firm’s fifty day moving average is $38.31 and its 200-day moving average is $41.63. The company has a quick ratio of 9.71, a current ratio of 9.73 and a debt-to-equity ratio of 0.07.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.02. The firm had revenue of $33.17 million during the quarter, compared to analysts’ expectations of $31.61 million. FibroGen had a net margin of 11.81% and a return on equity of 7.50%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.50) earnings per share. On average, analysts expect that FibroGen Inc will post -0.16 EPS for the current year.

In other FibroGen news, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $44.33, for a total value of $1,757,063.88. Following the completion of the transaction, the chief executive officer now directly owns 2,356,578 shares of the company’s stock, valued at $104,467,102.74. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Christine Chung sold 5,625 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $34.74, for a total transaction of $195,412.50. Following the completion of the transaction, the senior vice president now directly owns 145,253 shares of the company’s stock, valued at $5,046,089.22. The disclosure for this sale can be found here. Insiders have sold 92,381 shares of company stock valued at $3,839,495 over the last three months. 8.96% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in FibroGen by 8.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,726 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 378 shares in the last quarter. Doheny Asset Management CA increased its holdings in FibroGen by 1.6% in the second quarter. Doheny Asset Management CA now owns 36,471 shares of the biopharmaceutical company’s stock valued at $1,648,000 after buying an additional 586 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in FibroGen by 1.8% in the second quarter. State Board of Administration of Florida Retirement System now owns 40,364 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 720 shares in the last quarter. Zacks Investment Management increased its holdings in FibroGen by 2.8% in the second quarter. Zacks Investment Management now owns 26,642 shares of the biopharmaceutical company’s stock valued at $1,204,000 after buying an additional 738 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in FibroGen by 4.1% in the third quarter. Envestnet Asset Management Inc. now owns 22,334 shares of the biopharmaceutical company’s stock valued at $826,000 after buying an additional 881 shares in the last quarter. 69.03% of the stock is owned by institutional investors.

FibroGen Company Profile (NASDAQ:FGEN)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More: What is the 52-week high/low?

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.